Girona J, Guardiola M, Barroso E, Garcia-Altares M, Ibarretxe D, Plana N
Int J Mol Sci. 2025; 26(5).
PMID: 40076667
PMC: 11900571.
DOI: 10.3390/ijms26052039.
Fernandez-Ramos D, Lopitz-Otsoa F, Lu S, Mato J
Cancers (Basel). 2025; 17(3).
PMID: 39941901
PMC: 11816870.
DOI: 10.3390/cancers17030535.
Sato S, Iino C, Sasada T, Soma G, Furusawa K, Yoshida K
JGH Open. 2024; 8(12):e70043.
PMID: 39713746
PMC: 11659511.
DOI: 10.1002/jgh3.70043.
Franciscatto M, Taniguchi J, Wohlenberg R, Riedi I, Oppermann K
Rev Bras Ginecol Obstet. 2024; 46.
PMID: 39669304
PMC: 11637444.
DOI: 10.61622/rbgo/2024rbgo81.
Gbande P, Tchaou M, Djoko Makamto H, Dagbe M, Sonhaye L, Agoda-Koussema L
Ultrasound. 2024; 32(4):253-259.
PMID: 39493915
PMC: 11528735.
DOI: 10.1177/1742271X241241779.
Adaptation of Clinical Practice Guideline for Assessment of Liver Fibrosis in Patients with Non Alcoholic Fatty Liver Disease in Isfahan Province.
Hosseeini S, Jafari M, Tahmasebi M, Adibi P
Int J Prev Med. 2024; 15:27.
PMID: 39239302
PMC: 11376528.
DOI: 10.4103/ijpvm.ijpvm_284_22.
Metabolic Dysfunction-Associated Fatty Liver Disease and Fibrosis Status in Patients with Type 2 Diabetes Treated at Internal Medicine Clinics: Türkiye DAHUDER Awareness of Fatty Liver Disease (TR-DAFLD) Study.
Sahinturk Y, Koker G, Koca N, Sumbul H, Demir I, Keskin H
Turk J Gastroenterol. 2024; 35(8):643-650.
PMID: 39150440
PMC: 11363181.
DOI: 10.5152/tjg.2024.24045.
The Burden of Nonalcoholic Steatohepatitis: A Systematic Review of Epidemiology Studies.
Tapper E, Fleming C, Rendon A, Fernandes J, Johansen P, Augusto M
Gastro Hep Adv. 2024; 1(6):1049-1087.
PMID: 39131247
PMC: 11307414.
DOI: 10.1016/j.gastha.2022.06.016.
Loss-of-function G6PD variant moderated high-fat diet-induced obesity, adipocyte hypertrophy, and fatty liver in male rats.
Matsumura S, Signoretti C, Fatehi S, Tumenbayar B, DAddario C, Nimmer E
J Biol Chem. 2024; 300(7):107460.
PMID: 38876306
PMC: 11328872.
DOI: 10.1016/j.jbc.2024.107460.
Comparison of fatty liver index with fibroscan in non-alcoholic fatty liver disease.
Ahmed M, Saeed R, Kamani L, Durrani N, Ahmed F
J Family Med Prim Care. 2024; 13(4):1488-1495.
PMID: 38827715
PMC: 11141960.
DOI: 10.4103/jfmpc.jfmpc_1789_23.
The first selective VAP-1 inhibitor in China, TT-01025-CL: safety, tolerability, pharmacokinetics, and pharmacodynamics of single- and multiple-ascending doses.
Yang Y, Yu L, Sheng Z, Lin H, Weng Z, Song W
Front Pharmacol. 2024; 15:1327008.
PMID: 38741586
PMC: 11089243.
DOI: 10.3389/fphar.2024.1327008.
Probiotic supplementation for 24 weeks in patients with non-alcoholic steatohepatitis: the PROBILIVER randomized clinical trial.
Silva-Sperb A, Moraes H, Barcelos S, de Moura B, Longo L, Michalczuk M
Front Nutr. 2024; 11:1362694.
PMID: 38600992
PMC: 11004384.
DOI: 10.3389/fnut.2024.1362694.
17-Beta-Hydroxysteroid Dehydrogenase 13 Loss of Function Does Not Confer Protection to Nonalcoholic Fatty Liver Disease in Indian Population.
Govardhan B, Anand V, Rao P, Balachandran Menon P, Mithun S, Sasikala M
J Clin Exp Hepatol. 2024; 14(4):101371.
PMID: 38523737
PMC: 10956055.
DOI: 10.1016/j.jceh.2024.101371.
Assessment of the Relationship Between Liver Enzymes and Cardiovascular Disease: A Study in Bangladeshi Adults.
Hasan A, Newaj A, Trisha A, Hafsa J, Mohanto N, Ali N
Endocrinol Diabetes Metab. 2024; 7(2):e00481.
PMID: 38494432
PMC: 10944799.
DOI: 10.1002/edm2.481.
Gender perspective on the association between liver enzyme markers and non-alcoholic fatty liver disease: insights from the general population.
Qiu J, Kuang M, He S, Yu C, Wang C, Huang X
Front Endocrinol (Lausanne). 2023; 14:1302322.
PMID: 38125795
PMC: 10731038.
DOI: 10.3389/fendo.2023.1302322.
Unraveling the mechanisms of trans-cinnamic acid in ameliorating non-alcoholic fatty liver disease.
Solanki N, Patel R
Am J Transl Res. 2023; 15(9):5747-5756.
PMID: 37854239
PMC: 10579026.
Non-invasive assessment of steatohepatitis indicates increased risk of coronary artery disease.
Beer S, Babel J, Martin N, Blank V, Wiegand J, Karlas T
PLoS One. 2023; 18(9):e0286882.
PMID: 37768969
PMC: 10538770.
DOI: 10.1371/journal.pone.0286882.
A global survey of health care workers' awareness of non-alcoholic fatty liver disease: The AwareNASH survey.
Driessen S, de Jong V, van Son K, Klompenhouwer T, Colardelle Y, Alings M
United European Gastroenterol J. 2023; 11(7):654-662.
PMID: 37563849
PMC: 10493357.
DOI: 10.1002/ueg2.12445.
Relationship between Uric Acid to High Density Lipoprotein Cholesterol Ratio and Nonalcoholic Fatty Liver Disease in Nonoverweight/Obese Patients with Type 2 Diabetes.
Cui Y, Qu Z, Hu W, Shi H
Int J Endocrinol. 2023; 2023:2513175.
PMID: 37560201
PMC: 10409575.
DOI: 10.1155/2023/2513175.
From Non-Alcoholic Fatty Liver Disease to Liver Cancer: Microbiota and Inflammation as Key Players.
Rodriguez-Lara A, Rueda-Robles A, Saez-Lara M, Plaza-Diaz J, Alvarez-Mercado A
Pathogens. 2023; 12(7).
PMID: 37513787
PMC: 10385788.
DOI: 10.3390/pathogens12070940.
